RSS   Newsletter   Contact   Advertise with us

Pernix Therapeutics adds Gabriel Leung to board

Staff Writer | Morristown, N.J., USA | November 23, 2016
Pernix TherapeuticsNovember 23, 2016, Morristown, N.J., USA - Pernix Therapeutics Holdings, a specialty pharmaceutical business, announced the appointment of Gabriel Leung to its board of directors.
The Board also determined that Mr. Leung is an independent director and appointed him as chairperson of the Nominating Committee and as a member of the Audit and Compensation Committees.

Mr. Leung is currently Vice Chairman and Board member of NovoCure Limited, a publicly listed commercial-stage oncology company.

He was most recently Executive Vice President of OSI Pharmaceuticals, Inc. and President of OSI’s Oncology and Diabetes Business, from 2003 to 2010, prior to its acquisition by Astellas Pharma Inc.

Prior to his tenure at OSI, from 1999 to 2003, Mr. Leung served as Group Vice President of the global prescription business at Pharmacia Corporation, a global pharmaceutical and healthcare company.

From 1991 to 1999, he was an executive at Bristol-Myers Squibb Company.

In addition, Mr. Leung served as a director for Albany Molecular Research Inc. (AMRI), a global contract research and manufacturing company, from 2010 to 2016 and as a director of Delcath Systems, Inc. from 2011 to 2014, a specialty pharmaceutical and medical device company.

Mr. Leung earned his B.S. in Pharmacy with high honors at the University of Texas at Austin. He attended graduate school at the University of Wisconsin-Madison, where he earned his M.S. in Pharmacy, with a concentration in pharmaceutical marketing.